James Good

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno et al. · European Journal of Cancer · 2018 · 267 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106

Gerben R. Borst, Martin McLaughlin, Joan Kyula et al. · International Journal of Radiation Oncology*Biology*Physics · 2012 · 55 citations

Medicine, Oncology, Pharmacology +6

Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocol

Anthony Kong, James Good, Amanda Kirkham et al. · BMJ Open · 2020 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-<i>α</i>2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma

Robert Weber, Steven O’Day, Madalene Rose et al. · Journal of Clinical Oncology · 2005 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +17